StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Seattle Genetics (SGEN) Granted FDA Approves for Peripheral T-cell Lymphoma Treatment
November 16, 2018 10:49 AM
The U.S. Food and Drug Administration today expanded the approved use of Seattle Genetics' (NASDAQ: SGEN) Adcetris (brentuximab vedotin) injection ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Next Articles
Seattle Genetics (SGEN) Reports FDA Approval of ADCETRIS (Brentuximab Vedotin) in Combination with Chemotherapy
November 16, 2018 10:53 AM